Singapore, May 2 -- ShanghaiHenlius Biotech, Inc. announced a licensing agreement withSandoz, the global leader in generic and biosimilar medicines, granting exclusive commercialisation rights for its self-developed ipilimumab biosimilar HLX13 in the United States, 42 European countries and regions, Japan, Canada, and Australia.

Under the agreement, Henlius will be responsible for development, manufacturing and commercial supply of HLX13, and is eligible to receiveup to a total of $301 million,including a $31 million upfront and additional milestone payments.

As the global leader in generic and biosimilar medicines,Sandoz is committed to its purpose of "pioneering access for patients" and has benefited over 900 million patients worldwid...